Skip to main content
main-content

Oncology

16-04-2018 | Non-small-cell lung cancer | Highlight | Article

Editor's pick

Neoadjuvant nivolumab could benefit patients with resectable NSCLC

Neoadjuvant treatment with the PD-1 inhibitor nivolumab shows promising activity in patients with untreated surgically resectable early non-small-cell lung cancer, with few side effects, US researchers report.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

24-04-2018 | Oncology | News | Article

News in brief

Oral ketamine does not ease cancer-related neuropathic pain

A UK trial rules out the use of oral ketamine for the general treatment of chronic neuropathic pain in patients with cancer.

23-04-2018 | Melanoma | News | Article

Encorafenib–binimetinib a new option for BRAF-mutated melanoma

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate.

Source:

Lancet Oncol 2018; Advance online publication

20-04-2018 | Gastrointestinal cancer | News | Article

News in brief

Short-acting calcium channel blockers may increase pancreatic cancer risk

Postmenopausal women who take short-acting calcium channel blockers could be at increased risk for developing pancreatic cancer, findings indicate.

19-04-2018 | Non-small-cell lung cancer | News | Article

First-line pembrolizumab plus chemotherapy boosts advanced NSCLC outcomes

Adding pembrolizumab to standard chemotherapy significantly delays disease progression and improves overall survival in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer, KEYNOTE-189 data show.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

METIV-HCC Results Cast Doubt On Validity Of MET Inhibition In Advanced HCC

Treatment with the MET inhibitor tivantinib in the second line does not improve survival over placebo in patients with MET-high advanced hepatocellular carcinoma Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits